EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts

O W Bredewold, A M van Oeveren-Rietdijk, B Florijn, J I Rotmans, J W de Fijter, C van Kooten, A J van Zonneveld, H C de Boer

Transplant Immunology · 2024

DOI: 10.1016/j.trim.2023.101976 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Transplant Immunology, 2024. Verfasst von O W Bredewold und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, L…. Hauptthemen laut MEDLINE: Abatacept, Calcineurin Inhibitors, Immunosuppression Therapy, Kidney Transplantation. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Belatacept, a modified form of CTLA-Ig that blocks CD28-mediated co-stimulation of T cells, is an immune-suppressant that can be used as an alternative to calcineurin inhibitors (CNIs). In kidney transplant recipients, belatacept has been associated with improved renal function and reduced cardiovascular toxicity. Monocytes as well as T-lymphocytes play causal roles in the pathophysiology of atherosclerotic disease. We hypothesized that the beneficial impact of the use of belatacept over CNIs on cardiovascular risk could be partly explained by the impact of belatacept therapy on these circulating leukocytes. Hence, we phenotyped circulating leukocytes in transplanted patients with a stable renal function that were randomized between either continuation of CNI or conversion to belatacept in two international studies in which we participated. In 41 patients, we found that belatacept-treated patients consistently showed lower numbers of B-lymphocytes, T-lymphocytes as well as CD14-negative monocytes (CD14NM), especially in non-diabetic patients. Our observation that this decrease was associated to plasma concentrations of TNFα is consistent with a model where CD14NM-production of TNFα is diminished by belatacept-treatment, due to effects on the antigen-presenting cell compartment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptCalcineurin InhibitorsImmunosuppression TherapyKidney TransplantationHumansCell ProliferationGraft RejectionImmunosuppressive AgentsMonocytesTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Antigen presentationCalcineurin inhibitorCo-stimulation blockadeKidney transplantationMonocyte differentiation

Substanzen

AbataceptCalcineurin InhibitorsImmunosuppressive AgentsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands.. Electronic address: O.W.Bredewold@lumc.nl.
  • Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands.

Zitieren

APA

Bredewold, O. W., van Oeveren-Rietdijk, A. M., Florijn, B., Rotmans, J. I., de Fijter, J. W., van Kooten, C., van Zonneveld, A. J., & de Boer, H. C. (2024). Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts. Transplant Immunology. https://doi.org/10.1016/j.trim.2023.101976

Vancouver

Bredewold OW, van Oeveren-Rietdijk AM, Florijn B, Rotmans JI, de Fijter JW, van Kooten C, et al. Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts. Transplant Immunology. 2024. doi:10.1016/j.trim.2023.101976

BibTeX
@article{Bredewold2024,
  author = {Bredewold, O W and van Oeveren-Rietdijk, A M and Florijn, B and Rotmans, J I and de Fijter, J W and van Kooten, C and van Zonneveld, A J and de Boer, H C},
  title = {Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts},
  journal = {Transplant Immunology},
  year = {2024},
  doi = {10.1016/j.trim.2023.101976}
}
Kostenlos starten →